KLK3 and posterior cortical atrophy: TT administration led to fewer Pca patients (RR=0.62, 95%CI [0.39,0.99], I<sup>2</sup>=0%), while little decreasing in PSA level (MD=-0.05, 95%CI [-0.08, -0.02], I<sup>2</sup>=0%).